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Introduction
Rituximab (RTX) is an alternative for refractory patients
with renal SLE, as several open studies support but the
only randomized study did not find differences with
immunosuppressives. Our objective is to know if RTX is
effective for lupus nephritis refractory to immunosup-
pressive therapy.
Material and methods
We have followed up 46 SLE patients, diagnosed by
ACR criteria refractory to immunosuppressive therapy
from 3 Spanish hospitals, treated with RTX. The main
reason for use of RTX was nephritis in 11 patients
(23.9%), arthritis in 13 (28.3%), thrombocytopenia in
5 (10.9%), neurologic involvement in 6 (13%), cutaneous
in 6 (13%) and others 5 (10.9%). The dose used in most
patients was 2x 1g (86.7%).
Results
46 patients (6.5% men and 93.5% women). 91.3% Cauca-
sians. The most common dose used was 2x1g (86.7%).
The median of cycles was 2 (rank 1-3). Table 1.
In 11 renal SLE patients, 8 had complete and 3 partial
clinical remission.
Conclusions
RTX have been effective in a group of renal SLE refrac-
tory to immunosuppressive therapy (in 8 from 11 refrac-
tory renal SLE patients). We are indicating it for SLE
patients refractory to conventional therapy, but further
studies are necessary to establish its role in the treat-
ment of SLE.
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Table 1 Endpoints
Baseline 24th weeks Final Visit
Urinary Sediment (%) 37 9.5** 2.2*
24-hour urine protein
(gr/24h)
1.2 ± 2.01 0.34 ± 0.58** 0.22 ± 0.38**
C3 (mg/dl) 78.17 ± 31.08 91.3 ± 31.4** 101.4 ± 30.8*
C4 (mg/dl) 12.52 ± 7.95 16.31 ± 7.51** 19.16 ± 8.74*
Anti-DNA (UI) 34.6 (4.85-70.07) 26.1 (2.12-52.5) 13 (3.9-34)**
SLEDAI 14.5 (7.75-22.25) 4 (2-6)* 2 (0-4)*
Physician´s Global
Assessment (PGA)
2.75 (2.0-3.0) 0.0 (0.0-1.0)* 0.0 (0.0-1.0)*
*p < 0,0005 respect to baseline.
**p < 0.05 respect to baseline.
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